Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 46, 2008, Pages 17736-17741

  Russell, Rupert J ^a   Kerry, Philip S ^a   Stevens, David J ^b   Steinhauer, David A ^c   Martin, Stephen R ^b   Gamblin, Steven J ^b   Skehel, John J ^b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crystallography; Drug design

Indexed keywords

HEMAGGLUTININ;

ARTICLE; CRYSTAL STRUCTURE; INFLUENZA; MEMBRANE FUSION; PH; PHYLOGENY; PRIORITY JOURNAL;

BINDING SITES; FLUOROMETRY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HYDROGEN-ION CONCENTRATION; HYDROQUINONES; MEMBRANE FUSION; PHYLOGENY; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN SUBUNITS; SUBSTRATE SPECIFICITY;

EID: 56649120628     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807142105     Document Type: Article

References (41)

1. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 69:531-569.
2. Pinto LH, Lamb RA (2006) The M2 proton channels of influenza A and B viruses. J Biol Chem 281:8997-9000.
3. Murphy BR, Webster RG (1996) in Fields Virology, eds Fields DBN, Knipe M, Howley PM) (Lippincott-Raven, Philadelphia), 3rd Ed, pp 1397-1445.
4. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4:3021-3024.
5. Von Itzstein M, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
6. Kim CU, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119:681-690.
7. Ives J, et al. (2000) Antiviral drug resistance: An oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo. J Clin Virol 18:251-269.
8. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523-531.
9. Carr J, et al. (2002) Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 54:79-88.
10. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55(Suppl 1):i5-i21.
11. Hayden FG, Hay AJ (1992) Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176:119-130.
12. Centre for Disease Control and Prevention (2006) Epidemiology of HIV/AIDS-United States, 1981-2005. Morbid Mortal Wkly Rep 55:589-592.
13. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70:121-131.
14. Hoffman LR, Kuntz ID, White JM (1997) Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: Irreversible inhibition of infectivity. J Virol 71:8808-8820.
15. Bodian DL, et al. (1993) Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32:2967-2978.
16. Yu KL, et al. (2002) Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5- hydroxy-cyclohexylmethylamine. Bioorg Med Chem Lett 12:3379-3382.
17. De Clercq E (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5:1015-1025.
18. Wilson IA, Skehel JJ, Wiley DC (1981) Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3-Å resolution. Nature 289:366-373.
19. Bullough PA, Hughson FM, Skehel JJ, Wiley DC (1994) Structure of influenza hemagglutinin at the pH of membrane fusion. Nature 371:37-43.
20. Chen J, Skehel JJ, Wiley DC (1999) N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triplestranded coiled coil. Proc Natl Acad Sci USA 96:8967-8972.
21. Harrison SJ (2008) Viral membrane fusion. Nat Struct Mol Biol 15:690-698.
22. WHO (1980) A revision of the system of nomenclature for influenza viruses: A WHO memorandum. Bull WHO 58:585-591.
23. Fouchier RA, et al. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79:2814-2822.
24. Russell RJ, et al. (2004) H1 and H7 influenza hemagglutinin structures extend a structural classification of hemagglutinin subtypes. Virology 325:287-296.
25. Thoennes S, et al. (2008) Analysis of residues near the fusion peptide in the influenza hemagglutinin structure for roles in triggering membrane fusion. Virology 370:403-414.
26. Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M (1999) Automated analysis of interatomic contacts in proteins. Bioinformatics 15:327-332.
27. Shangguan T, Alford D, Bentz J (1996) Influenza virus-liposome lipid mixing is leaky and largely insensitive to the material properties of the target membrane. Biochemistry 35:4956-4965.
28. Rogers GN, et al. (1983) Single amino acid substitutions in influenza hemagglutinin change receptor binding specificity. Nature 304:76-78.
29. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417-427.
30. Steinhauer DA, Wharton SA, Skehel JJ, Wiley DC, Hay AJ (1991) Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: Evidence for virus-specific regulation of the pH of glycoprotein transport vesicles. Proc Natl Acad Sci USA 88:11525-11529.
31. Ha Y, Stevens DJ, Skehel JJ, Wiley DC (2001) X-ray structures of H5 avian and H9 swine influenza virus hemagglutinins bound to avian and human receptor analogs. Proc Natl Acad Sci USA 98:11181-11186.
32. Otwinowski Z, Minor W (1993) in Data Collection and Processing, eds Sawyer L, Isaacs N, Bailey S) (SERC Daresbury Laboratory, Warrington, U.K.), pp 556-562.
33. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40:658-674.
34. CCP4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D 50:760-763.
35. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D 58:1948-1954.
36. Jones TA, Zhou JY, Cowan SW, Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119.
37. Niesen FH, Berglund H, Vedadi M (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protocols 9:2212-2221.
38. DeLano WL (2002) The PyMOL Molecular Graphics System (DeLano Scientific, Palo Alto, CA).
39. Bizebard T, et al. (1995) Structure of influenza virus hemagglutinin complexed with a neutralizing antibody. Nature 37:92-94.
40. Trooskens G, De Beule D, Decouttere F, Van Criekinge W (2005) Phylogenetic trees: Visualizing, customizing and detecting incongruence. Bioinformatics 21:3801-3802.
41. Mayhood TM, Windsor WT (2005) Ligand binding affinity determined by temperature-dependent circular dichroism: Cyclin-dependent kinase 2 inhibitors. Anal Biochem 345:187-197.